Statement: the secondary trial administers placebo tablets at twice the rate of the primary trial, but less than half the dose.
Primary_evidence: INTERVENTION 1:    Breast Cancer Patients   Tomosynthesis Breast Scanning is done and breast CT Scanning is done.
Secondary_evidence: INTERVENTION 1:    Pralatrexate   Study drug 190 mg/m^2 for 2 to 4 weeks.